Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 21,040 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Type 2 Diabetes
Interventions: Diabetes Homeless Medication Support, Enhanced Usual Care/ Education; Behavioral
Lead sponsor: Katherine Vickery; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertension, Hemodialysis
Interventions: Digoxin immune fab, Placebo; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Kidney Transplantation, Graft Rejection
Interventions: Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA), Basiliximab, Corticosteroids; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 833 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Facial Flushing
Interventions: botulinum toxin A, Saline Control; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: Instrument Assisted Soft Tissue Mobilization first Control second, Control first Instrument Assisted Soft Tissue Mobilization second; Other
Lead sponsor: Beth Marschner; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Minot, North Dakota

Conditions: Cataract
Interventions: Dextenza Ophthalmic Insert, Prednisolone acetate ophthalmic suspension USP 1%; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: 0 Years to 5 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 14
States / cities: Aurora, Colorado • Fort Collins, Colorado • Jacksonville, Florida + 11 more

Conditions: Stroke
Interventions: Social Phone Calls; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Increased Breastfeeding
Interventions: Team2BF, Bright By Text; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Safety of Neosaxitoxin in Healthy Volunteers
Interventions: Neosaxitoxin in saline, NeoSTX + bupivacaine 0.2%, NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml, Saline placebo; Drug · Other
Lead sponsor: Charles Berde; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malignant Pleural Mesothelioma (MPM)
Interventions: cyclophosphamide, CAR T cells; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Platelet Aggregation
Interventions: Plavix® and PA32540, EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®); Drug
Lead sponsor: POZEN; Industry
Eligibility: 40 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV
Interventions: patient activation training, Usual care; Behavioral · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: New York, New York • Rochester, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 9
States / cities: Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more

Conditions: Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
Interventions: Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization; Drug · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Health Knowledge, Attitudes, Practice, Health Care Utilization
Interventions: Patient education materials, Physician peer-comparison email, Physician education materials, General visit preparation materials; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization, Subretinal Scarring, Subretinal Fibrosis
Interventions: RXI-109; Drug
Lead sponsor: RXi Pharmaceuticals, Corp.; Industry
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate; Drug
Lead sponsor: Retina Vitreous Associates of Florida; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Disorders of Gut Brain Interaction
Interventions: Mannitol Solution 76 mOsm/L, Mannitol Solution 189 mOsm/L, Mannitol Solution 325 mOsm/L, Scintigraphy; Drug · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Head and Neck Cancer
Interventions: DCE-MRI, DW-MRI and MRS; Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Interventions: Dupilumab, Pembrolizumab, Paclitaxel, Carboplatin; Drug
Lead sponsor: Rima Patel; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Knee Osteoarthritis, Total Knee Replacement
Interventions: Telephonic Active Coaching (Motivational Interviewing) + Financial Incentives, Wrist based activity tracker wear, Basic Study Activities; Behavioral · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 85 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: Chicago, Illinois • Kansas City, Kansas • Boston, Massachusetts + 2 more

Conditions: Diaphyseal Femur Fracture
Interventions: Transesophageal transducer, echocardiography; Procedure
Lead sponsor: University of Kentucky; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Healthy, Insulin Resistance
Interventions: Neuromuscular Test, DEXA, Mixed Meal Tolerance Test, Strength Test; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 60 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Glaucoma, Age Related Macular Degeneration, Optic Neuropathy, Retinal Degeneration
Interventions: nGoggle; Device
Lead sponsor: NGoggle; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 200 participants
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Effectiveness of the Diabetes Homeless Medication Support (D-HOMES) Program on Diabetes Management

Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

Treatment of Facial Flushing With Botulinum Toxin A Injections

Effects of Instrument Assisted Soft Tissue Mobilization Regarding Range of Motion and Lower Extremity Power

A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract

The Impact of Social Phone Calls on Adults Who Have Had a Stroke

Texting to Promote Breastfeeding (TOPS)

Safety Study of Long-Acting Local Anesthetic

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

Get Ready And Empowered About Treatment

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

Shared Decision-making on Medical Tests and Care Cascades

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections

Development of a Noninvasive Metric to Measure Small Bowel Sensation - The Small Intestine Stress Test

Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Knee Arthroplasty Activity Trial

A Prospective Study to Determine the Effectiveness of Reaming in Reducing Fat Emboli to the Lungs

A Comparison of Neuromuscular Recruitment in Trained and Untrained Adults

Assessment of Visual Function With a Portable Brain-computer Interface